2022 Biotech Investing Forecast

After what has undoubtedly been a very rocky 12 months for biotech, is the sector ripe for a comeback? Biotech investor and Harvard-trained medical doctor, Dr. Christiana Bardon thinks advances in gene therapies, robust drug pipelines and an improving regulatory landscape will be key industry drivers for the road ahead.
Fri, Apr 15 202212:01 AM EDT